CRB 217
Alternative Names: CRB-217Latest Information Update: 15 Feb 2024
At a glance
- Originator Celros Biotech
- Class Eye disorder therapies
- Mechanism of Action NADPH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration
Most Recent Events
- 14 Feb 2024 Preclinical trials in Age-related macular degeneration in South Korea (Opthalmic) prior to February 2024 (Celros Biotech pipeline, February 2024)
- 14 Feb 2024 Celros Biotech plans a phase I trial for Age-related macular degeneration (Ophthalmic) (Celros Biotech pipeline, February 2024)